Vascular Solutions' (VASC) Fluent Inflation Device Receives FDA 510(k) Clearance
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Vascular Solutions, Inc. (Nasdaq: VASC) announced that it has received 510(k) clearance from the U.S. Food and Drug Administration for the Fluent inflation device for use during cardiovascular procedures to create, maintain, and monitor pressure in balloon catheters. Fluent received CE Mark clearance in August 2016 and has already begun international clinical evaluations. Vascular Solutions expects to commence the commercial launch of Fluent in the U.S. and Europe during the fourth quarter.
“Every angioplasty procedure requires the use of an inflation device, and we are pleased that today’s FDA clearance to market Fluent will allow us to expand our presence in this large, yet competitive, market,” said Howard Root, Chief Executive Officer of Vascular Solutions. “The internally-developed and manufactured Fluent has design and performance characteristics that we believe will make it a popular choice for physicians who perform a wide range of interventional procedures, particularly when combined with Vascular Solutions’ widely-used Guardian hemostasis valves in a convenient interventional pack configuration.”
The Fluent inflation device features a 25cc barrel and creates pressures up to 30 atmospheres of mercury (atm). The ergonomic design provides a system that is easy to fill, flush, and operate. The locking mechanism is marked to show locked and unlocked positions. The pressure gauge glows in the dark so that it is easily readable under low light conditions in the cath lab.
Vascular Solutions will offer the Fluent inflation device in 10 configurations to meet a wide variety of procedural requirements: packaged separately and as a kit including the Guardian hemostasis valve and other angioplasty accessories.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teva Pharma (TEVA) Announces FDA Approval for VANTRELATM ER with Abuse Deterrence Technology
- Jazz Pharmaceuticals (JAZZ) Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for Prevention of VOD
- McKesson in record $150 million U.S. settlement over suspicious drug orders
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!